% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Saalfeld:169803,
      author       = {F. C. Saalfeld and C. Wenzel and P. Christopoulos and S.
                      Merkelbach-Bruse and T. M. Reissig and S. Laßmann and S.
                      Thiel and J. A. Stratmann and R. Marienfeld and J. Berger
                      and A. Desuki and J.-L. Velthaus and D. Kauffmann-Guerrero
                      and A. Stenzinger and S. Michels and T. Herold and M. Kramer
                      and S. Herold and A. Tufman and S. Loges$^*$ and J. Alt and
                      M. Joosten and G. Schmidtke-Schrezenmeier and M. Sebastian
                      and S. Stephan-Falkenau and C. F. Waller and M. Wiesweg and
                      J. Wolf and M. Thomas and D. E. Aust and M. Wermke},
      collaboration = {n. L. Cancer},
      title        = {{B}rief {R}eport: {E}fficacy of immune checkpoint
                      inhibitors alone or in combination with chemotherapy in
                      {NSCLC} harboring {ERBB}2 mutations.},
      journal      = {Journal of thoracic oncology},
      volume       = {16},
      number       = {11},
      issn         = {1556-0864},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2021-01557},
      pages        = {1952-1958},
      year         = {2021},
      note         = {2021 Nov;16(11):1952-1958},
      abstract     = {In contrast to other driver mutations, no targeted
                      therapies have yet been approved in ERBB2 mutated non-small
                      cell lung cancer (HER2mu NSCLC). However, several compounds
                      have shown promising early efficacy data, which need to be
                      evaluated in the context of current standard approaches.
                      While data on the efficacy of immune checkpoint inhibitors
                      (ICI) in second or later lines of treatment remain limited
                      and conflicting, there are virtually no data on patient
                      outcome under ICI / platinum doublet combinations in the
                      first-line setting.We retrospectively assessed outcomes of
                      HER2mu NSCLC patients treated with ICI alone or in
                      combination with chemotherapy within the German nNGM
                      consortium by means of overall response rate (ORR),
                      progression-free, and overall survival (PFS and OS).ICI
                      either in combination with chemotherapy or as monotherapy
                      were applied as first-line treatment in 27 patients, whereas
                      34 received single agent ICI in second or later lines.
                      Patient characteristics were in line with previously
                      published data. In treatment-naïve patients receiving ICI
                      in combination with chemotherapy the ORR, median PFS, and OS
                      rate at 1 year were $52\%,$ 6 months, and $88\%,$
                      respectively. In second or later lines ICI monotherapy was
                      associated with an ORR of $16\%,$ a median PFS of 4 months,
                      and a median OS of 10 months.Immune checkpoint inhibitors
                      are effective as monotherapy and in combination with
                      platinum doublet chemotherapy. Therefore, ICI based
                      treatments may be seen as the current standard of care and
                      benchmark for targeted therapies in HER2mu NSCLC.},
      keywords     = {HER2 (Other) / Immunotherapy (Other) / NSCLC (Other)},
      cin          = {A420},
      ddc          = {610},
      cid          = {I:(DE-He78)A420-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34245914},
      doi          = {10.1016/j.jtho.2021.06.025},
      url          = {https://inrepo02.dkfz.de/record/169803},
}